TMCnet News

PROT,NTS, & PRXL Researching For Cures by Stock-PR.com
[August 07, 2010]

PROT,NTS, & PRXL Researching For Cures by Stock-PR.com


Stock-PR Reporting FREE Daily Stock Alerts From Stock-PR.com ________________________________________ Proteonomix, Inc. (PROT.OB), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, reported that it has retained Wolfe Axelrod Weinberger Associates LLC as its investor relations agency effective immediately.



Michael Cohen, Chairman, President & CEO of Proteonomix, stated, "We've retained Wolfe Axelrod Weinberger Associates to assist us in communicating our unique strategy to the financial community to improve investor awareness. We believe an active investor relations program will broaden our investor exposure and we believe that Wolfe Axelrod Weinberger will provide us with seasoned experience in this area." Wolfe Axelrod Weinberger Associates brings to its clients thirty years of successful investor relations experience and an extensive network of contacts. Wolfe Axelrod Weinberger Associates looks forward to working closely with Proteonomix, to accomplish its long-term objective of increasing shareholder value.

Proteonomix's research and development is focused on stem cell therapies for diabetes and cardiac injury. Proteonomix has plans to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells that will serve as a catalyst for bringing feasible therapies to market. Umbilical cord blood stem cells are already recognized as a viable treatment for more than 80 diseases, a number that will continue to grow. With this in mind, Proteonomix is preparing to establish a cord blood bank that employs proprietary technology that will lead to a significant increase the donor-recipient match rate. Proteonomix will also be launching a genetic diversity program to increase participation of minority groups that are currently under-represented in the pool of available cord blood stem cell units.


Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromalCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromalCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

National Technical Systems, Inc. (Nasdaq:NTSC), a leading provider of engineering services, disclosed that Chief Technology Officer Osman Sakr has been given an expanded leadership role in technology development in support of NTS' strategic, companywide Innovation Growth Program. Sakr, a 30-year veteran of high technology product development and implementation, will report directly to Douglas Briskie, Senior Vice President and Development Officer, who is leading the innovation initiative. "The Innovation Growth Program is one of several key companywide initiatives launched within the past 12 months targeted at furthering the Company's capabilities and geographic reach and aimed at driving growth", said CEO William McGinnis. "The overall plan is to develop closer relationships with the Company's global customer base and become the supplier of choice for a broader range of services", McGinnis said.

"We continue to invest significant time, energy and resources into creating an expanded, more comprehensive set of capabilities at NTS," McGinnis said. "Our new initiatives, which include the Innovation Growth Program, also involve an acquisition strategy designed to increase our capabilities, expand our geographic footprint and provide top talent for all levels of our organization. We want our customers and our potential customers to see that we are a more innovative and more comprehensive company, and that we are focused on outpacing our competition and becoming the customers' vendor of choice." The innovation strategy involves development and implementation around new services, new locations and emerging technology markets to convert new ideas into value for customers. Examples of recent promising capabilities currently being launched as a result of recent innovation efforts are high intensity radiated field (HIRF) testing, solar loading testing and enhancements of pyro shock testing for the aerospace and defense markets. Another example is thermal modeling, simulation and test (TMST), a certification program for the telecom industry to procure more energy efficient network equipment. Business plans forged last year under the innovation program have resulted in an expansion of offerings and market coverage of the Silicon Valley, CA and Plano, TX operations for the Aerospace and Telecom sectors. Innovation projects currently under evaluation in the active development cycle include, for instance, additional service offerings for the Alternative Energy market segments, further expansion into Asia, and adding new capabilities for space launch vehicles.

"The Innovation Growth Program was initially created to promote innovation within NTS, expand the company's capabilities and services and to position NTS as a leader in strategic product and market development", Briskie said.

"NTS has always been an innovative company, but we now are much more focused and more strategic," Briskie said. "In the past, our innovation successes resulted from random ad hoc efforts. Now it is a formalized process focused on a market driven strategy. We manage our innovation projects as a portfolio of competing opportunities along the short-, mid-, and long-term time horizons. We work to balance the creative entrepreneurial energy and value creation. This means lots of market research, formal business plans and financial analysis. We are far along in developing an internal innovation ecosystem to drive organic growth for NTS through innovation, in terms of product development and market development." Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq:PRXL), this week reported the results of a survey conducted during its recent webinar entitled ?Using Advanced Functionality of EDC to Simplify Workflow.? Perceptive polled biopharmaceutical industry professionals across a broad range of clinical and IT functions about the value of technological advances related to the increased use of Electronic Data Capture (EDC) in clinical development.

Survey results revealed the majority of respondents (66%) believe that the most valuable technological advance related to EDC is the convergence of systems to minimize redundant data entry at sites. A smaller group of respondents (26%) cited the value of dashboard reports available through EDC to enable greater visibility into trial performance metric data. Other EDC-related advances noted by survey participants included single sign-on for systems used at sites and web-enabled designer tools to facilitate collaboration.

According to Bill Byrom, Ph.D., Senior Director, Product Strategy, Perceptive Informatics, ?From a clinical site user's perspective, the EDC system represents the primary solution that performs patient-related tasks such as data collection. In studies using more than one technology, a user may need to log into other solutions to perform related activities. While data integration can eliminate a level of inefficiency and duplication between systems, there is still a need to log in and out of different applications within a single clinical trial. Our survey results indicate that site users benefit from a more streamlined approach to simplify their workflow. Product convergence, which is changing the way technologies can be used together, makes the clinical trial process more efficient by allowing the functionality that exists in one application to be accessed through another." The webinar examined how EDC systems are advancing to include new features that enable sponsors to rapidly collect cleaner clinical data and reduce training costs. The benefits of converging Randomization and Trial Supply Management (RTSM) technologies with EDC systems to streamline workflow and the value of integrating real-time ePRO data with EDC systems were discussed, as well as the utility of dashboards to view overall study performance.

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO).

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB) Sign Up For Free Stock Alerts At http://stock-pr.com/signup ________________________________________ Be Sure To Visit stock-pr.ning.com ********************************************************************** The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.

As a community-building service, TMCnet allows user submitted content which is not always proofed by TMCnet editors. If you feel this entry is of inferior quality or wish to report it for some reason, please forward the URL to "webedit [AT] tmcnet [DOT] com" with your comments.


[ Back To TMCnet.com's Homepage ]